IXICO PLC has strengthened its scientific advisory board by adding three senior specialists in Alzheimer’s and Parkinson’s diseases. The company also launched a new research collaboration with the Paris Brain Institute to improve MRI imaging techniques for Parkinson’s clinical trials using AI-driven analysis. This expansion and partnership aim to enhance the reliability of biomarkers in neuroscience research, supporting IXICO’s role in advancing biopharma services. Key IXICO scientists have also joined The Michael J. Fox Foundation’s MRI Advisory Committee to standardize MRI biomarkers for Parkinson’s disease.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
In 2026, Alphabet has delivered outstanding returns over one, three, and five years, contrasting with struggles faced by other hyperscalers. The semiconductor sector remains highly cyclical, impacting both business performance and stock prices. A com...
IES Holdings has been upgraded to a Buy rating due to a record backlog increase of 63% to $3.9 billion and ongoing capacity expansion. The company’s Communications and Infrastructure Solutions segments, which have higher margins and growth potential,...
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
